GC Aesthetics® Announces Decade-Long Clinical Evaluation of PERLE™ Breast Implants
Dublin, Ireland – December 18th, 2024- GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets, is proud to announce the initiation of a significant multi-centre and prospective clinical study in Europe to evaluate, and confirm, the safety, effectiveness, and patient satisfaction associated with the innovative PERLE™ smooth opaque round breast implant.
This extensive study brings together leading surgeons from the NHS and private clinics in the UK, as well as from private practices across Europe, ensuring a robust and diverse dataset that addresses both cosmetic and reconstructive indications.
“By generating high-quality clinical evidence, we aim to provide unparalleled insights into the performance and patient benefits of the PERLE™ implant, setting a new standard for breast implant technology and patient care.” – Chris Brotherston, Head of QA / RA and Clinical Affairs at GC Aesthetics®.
PERLE™ is a highly innovative line of smooth opaque breast implants that feature a proprietary surface technology (BioQ™), GCA®’s industry-leading gel technology (Emunomic™ Breast Tissue Dynamic Gel), plus an enhanced version of the safety features that have underpinned GCA®’s long-term excellent safety record.
“Perle is a unique and innovative implant and long-term data on safety and efficacy will aid patients and clinicians to make informed choice with confidence. Perle study involves robust and extensive data collection with a large sample” commented Ms Nabila Nasir, Consultant Breast and Oncoplastic Surgeon MBBS, BSc, FRCS
Strategic Commitment to Innovation and Evidence-Based Solutions
“This study demonstrates GCA®’s approach to sustainable growth and value creation through clinically validated innovation. The findings will not only strengthen our product portfolio but also reinforce GCA®’s reputation for delivering high-quality, safe, and patient-centric solutions. By investing in rigorous, long-term clinical research, GCA® continues to position itself as a trusted partner for healthcare providers and women around the world.” Carlos Reis Pinto, CEO of GC Aesthetics concluded.
As part of GCA®’s strategic focus on innovation and evidence-based clinical advancements, this study highlights the commitment to meeting the evolving needs of patients and surgeons worldwide.